Corvus Pharmaceuticals 2025 Annual Meeting results: all proposals approved

Corvus Pharmaceuticals, Inc.

Elected Class III directors Ian T. Clark (28.9M for, 10.4M withheld) and Peter A. Thompson (38.8M for, 0.4M withheld).
Ratified PricewaterhouseCoopers as independent auditor for FY2025: 53.1M for, 0.1M against, 0.1M abstain.
Non-binding advisory vote on named executive officer compensation passed: 37.1M for, 2.1M against, 63.8k abstain.
53.4M shares voted of 68.2M outstanding; broker non-votes of 14.1M on director and compensation proposals.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.